A clinical trial study from the United States found that RPC patients who received preoperative selicrelumab exhibited tumor fibrosis and greater T-cell enrichment, suggesting that neoadjuvant chemotherapy with the CD40 monoclonal antibody selicrelumab altered the tumor microenvironment in resectable pancreatic cancer [33]. This evidence concerns the gene CD40 and neoplasm.